Chinese biotech Ascentage Pharma ... from Chinese biotechs – a trend that analyst Tim Opler believes is "just getting started." According to its IPO prospectus, Ascentage will use the net ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly ... deals and financial services trends, sign up for Finance Docket ...

This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a ...

Bluejay Therapeutics, a drug developer focused on serious viral and liver diseases, is considering a US initial public offering, according to people familiar with the matter.

March 7, 2025 (Investorideas.com Newswire) Investorideas.com, a recognized top 100 investment site for stock news announces ...

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more ...

This was the fourth biotech IPO of 2025, and the company raised around $219 million in its IPO, intended to advance its cystic fibrosis treatments. That is a market dominated Vertex ...

This week, Germany-based Anbio Biotechnology (NNNN) is expected to raise capital during its IPO. "NNNN is seeking US public capital market investment as it aims to commercialize its in vitro ...

Paramesu Biotechs IPO aims to raise ₹600 crore for expansion and debt repayment, showcasing strong financial performance and ...

Oncolytics Biotech Inc. (ONCY ... as indicated by its RSI reading of 27.83. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.

Cornerstone Research recently issued its 2024 Year in Review report examining recent trends in securities ... Filings against biotechnology companies surged – as did cases relating to artificial ...